NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $0.35 -0.01 (-2.76%) (As of 09/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends Get Entero Therapeutics alerts: Email Address About Entero Therapeutics Stock (NASDAQ:ENTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$0.34▼$0.3850-Day Range$0.24▼$1.1252-Week Range$0.19▼$14.51Volume32,164 shsAverage Volume325,267 shsMarket Capitalization$871,200.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEntero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Read More… Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Entero Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 34th PercentileEntero Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Entero Therapeutics.Read more about Entero Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entero Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.52) per share.Price to Book Value per Share RatioEntero Therapeutics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entero Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.42% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently decreased by 80.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntero Therapeutics does not currently pay a dividend.Dividend GrowthEntero Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.42% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently decreased by 80.59%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.44 News SentimentEntero Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for ENTO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,044.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of Entero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.30% of the stock of Entero Therapeutics is held by institutions.Read more about Entero Therapeutics' insider trading history. Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTO Stock News HeadlinesEntero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-QAugust 23, 2024 | globenewswire.comEntero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development ProgramJuly 31, 2024 | globenewswire.comBig News: How the Upcoming Rate Cut and Elon Musk’s AI Could Transform Your InvestmentsThe Federal Reserve is almost certainly about to cut interest rates, and history tells us that stocks often rally after such moves. In fact, based on my calculations, in seven out of nine rate-cut cycles since 1981, stocks have surged, delivering an average of 36.3% returns over two years. But that's not all... This time, there's another massive trigger on the horizon – Elon Musk's groundbreaking AI technology.September 18, 2024 | InvestorPlace (Ad)Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac DiseaseJune 27, 2024 | globenewswire.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $2.94 at the beginning of the year. Since then, ENTO stock has decreased by 88.0% and is now trading at $0.3520. View the best growth stocks for 2024 here. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/18/2024Next Earnings (Estimated)9/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTO CUSIPN/A CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.83% Return on Assets-22.74% Debt Debt-to-Equity Ratio0.40 Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.15Miscellaneous Outstanding Shares2,475,000Free Float2,463,000Market Cap$871,200.00 OptionableN/A Beta1.37 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ENTO) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersJoin Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading ...Monument Traders Alliance | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.